The Knowledge: Gentronix launches new assay screening service

GENTRONIX, the Manchester-based genotoxicity screening company, has added a new screening service, Ames MPF, to its portfolio.

The company uses its assays to allow drug companies to carry out tests on how new compounds alter genetic structures.

It said the new screening service allows drug companies to identify which compounds are likely to produce positive results in the regulatory Ames mutgageneticity test at an early stage, meaning that drug companies don’t waste time and money on compounds that are likely to mutate gene structures.

Gentronix’s commercial director Dr. Steve Beasley, said: “Early identification of genotoxic compounds saves time and money.

“We have developed an exceptional capability with our proprietary GreenScreen HC and BlueScreen HC reporter based technology and see the introduction of our Ames MPF screening service as providing an excellent integrated approach to help our customers increase their research efficiency.”